A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2018
At a glance
- Drugs Amlodipine (Primary) ; Sacubitril/valsartan (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 01 Jan 2018 Results assessing effect of sacubitril/valsartan on whole body and adipose tissue lipolysis, energy expenditure and substrate oxidation during defined physical exercise published in the Hypertension
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.